IP Library Patent Application 13125795
Patent Application
App. No. 13/125,795

Recombinant FcRn and Variants Thereof for Purification of Fc-Containing Fusion Proteins

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/125,795
Abstract

The invention is directed to methods of purifying Fc-containing molecules using a soluble neonatal Fc receptor (sFcRn). Native FcRn binds Fc-containing proteins at or below about pH 6.5 and releases them at or above about pH 7 and provides a much milder approach for capturing and purifying Fc-containing proteins, in particular, therapeutic Fc-containing proteins. Other embodiments of the invention provide modifications to alter the pH for binding and elution to the sFcRn, to modulate Fc-containing protein binding affinity, to affect sFcRn linkage to a support surface, or to improve the stability of sFcRn to conditions utilized in the methods of the invention.

Claims (127)

1 . A method of purifying an Fc-containing protein from a sample, the method comprising:

(a) contacting a sample containing said Fc-containing protein with soluble neonatal Fc receptor (sFcRn) bound to a support surface under conditions that allow said Fc-containing protein to bind sFcRn;

(b) separating said Fc-containing protein from the sample;

(c) dissociating said Fc-containing protein from the sFcRn; and

(d) collecting said Fc-containing protein.

2 . The method of claim 1 , wherein said Fc-containing protein is an enzymatically-active protein:Fc fusion protein.

3 . The method of claim 1 , wherein said Fc-containing protein is a Factor VIII:Fc fusion protein.

4 . A method of increasing the biological activity of an Fc fusion protein in a sample, the method comprising:

(a) contacting a sample containing said fusion protein with soluble neonatal Fc receptor (sFcRn) bound to a support surface under conditions that allow said Fc fusion protein to bind sFcRn;

(b) separating said Fc fusion protein from the sample;

(c) dissociating said Fc fusion protein from the sFcRn; and

(d) collecting said Fc fusion protein.

5 . The method according to claim 4 , wherein said Fc fusion protein is selected from the group consisting of an enzymatically active protein:Fc fusion protein and a Factor VIII:Fc fusion protein.

6 . The method of claim 1 , wherein the percent purity, by weight, of said Fc-containing protein collected, compared to the sum weight of associated contaminants, is a percent purity selected from the group consisting of:

(a) at least about 20% pure;

(b) at least about 30% pure;

(c) at least about 40% pure;

(d) at least about 50% pure;

(e) at least about 60% pure;

(f) at least about 70% pure;

(g) at least about 80% pure;

(h) at least about 85% pure;

(i) at least about 90% pure;

(j) at least about 95% pure,

(k) at least about 98% pure; and

(l) at least about 99% pure.

7 . The method of claim 1 , wherein the percent recovery, by weight, of said Fc-containing protein collected, compared to the sum weight of Fc-containing protein in said sample, is a percent recovery selected from the group consisting of:

(a) at least about 20% recovery;

(b) at least about 30% recovery;

(c) at least about 40% recovery;

(d) at least about 50% recovery;

(e) at least about 60% recovery;

(f) at least about 70% recovery;

(g) at least about 80% recovery;

(h) at least about 85% recovery;

(i) at least about 90% recovery;

(j) at least about 95% recovery,

(k) at least about 98% recovery; and

(l) at least about 99% recovery.

8 . The method of claim 4 , wherein the fold increase in the biological activity of said Fc fusion protein collected, compared to the biological activity of Fc fusion protein in said sample, is a fold increase selected from the group consisting of:

(a) at least about 2-fold;

(b) at least about 5-fold;

(c) at least about 10-fold;

(d) at least about 20-fold;

(e) at least about 50-fold;

(f) at least about 100-fold;

(g) at least about 200-fold;

(h) at least about 500-fold;

(i) at least about 1000-fold;

(j) at least about 2000-fold;

(k) at least about 5000-fold; and

(l) at least about 10000-fold.

9 . The method of claim 1 , wherein one or both heavy chain (α-chain) or light chain (β2m) domains of said sFcRn are modified to increase or decrease the affinity of Fc-containing protein binding.

10 . The method of claim 9 , wherein said modification comprises a change selected from the group consisting of:

(a) one or more amino acid substitutions;

(b) one or more amino acid deletions;

(c) one or more amino acid insertions;

(d) a post-translational chemical modification; and

(e) a modification which increases the binding affinity of sFcRn to Fc-containing proteins.

11 . (canceled)

12 . (canceled)

13 . The method of claim 1 , wherein one or both heavy chain (α-chain) or light chain (β2m) domains of said FcRn are modified to modulate linkage to the support surface wherein said modification increases efficiency of Fc-containing protein purification.

14 . (canceled)

15 . The method according to claim 13 wherein the modification increases sFcRn linkage to the surface.

16 . (canceled)

17 . The method of claim 1 , wherein one or both heavy chain (α-chain) or light chain (β2m) domains of said FcRn are modified to increase the stability of sFcRn binding activity.

18 . The method of Claim 1 , wherein the sFcRn α-chain and β2m are chemically, photo, or thermally cross-linked.

19 . The method of claim 1 , wherein the sFcRn α-chain and β2m are covalently linked by an amino acid linker.

20 . The method according to claim 19 , wherein the amino acid linker comprises (GGGGS)n, wherein n is between 1 and 5.

21 . The method of claim 1 , wherein the sFcRn is a human sFcRn.

22 . The method of claim 1 , wherein the support surface comprises SEPHAROSE™, agarose, silica, collodion charcoal, sand, polystyrene, or methacrylate.

23 . The method of claim 1 , wherein the sFcRn is bound to a support surface through formation of a bond selected from the group consisting of:

(a) a covalent bond;

(b) an amide bond;

(c) an amine bond;

(d) a carbon bond;

(e) a disulfide bond;

(f) an ester bond;

(g) an ether bond;

(h) a thioether bond;

(i) a urea bond; and

(j) a thiourea bond.

24 . (canceled)

25 . The method of claim 1 , wherein the sFcRn is bound to a support surface through a chemically, photo, or thermally activated cross-link.

26 . The method of claim 1 , wherein said method comprises contacting the sample containing said Fc-containing protein with sFcRn at or below a pH selected from the group consisting of:

(a) about 7.0;

(b) about 6.9;

(c) about 6.8;

(d) about 6.7;

(e) about 6.6;

(f) about 6.5;

(g) about 6.4;

(h) about 6.3;

(i) about 6.2;

(j) about 6.1;

(k) about 6.0;

(l) about 5.9;

(m) about 5.8;

(n) about 5.7;

(o) about 5.6;

(p) about 5.5;

(q) about 5.0;

(r) about 4.5; and

(s) about 4.0.

27 . (canceled)

28 . The method of claim 1 , wherein said method comprises dissociating the Fc-containing protein from sFcRn at or above a pH selected from the group consisting of:

(a) about 7.0;

(b) about 7.1;

(c) about 7.2;

(d) about 7.3;

(e) about 7.4;

(f) about 7.5;

(g) about 7.6;

(h) about 7.7;

(i) about 7.8;

(j) about 7.9;

(k) about 8.0;

(l) about 8.1;

(m) about 8.2;

(n) about 8.3;

(o) about 8.4;

(p) about 8.5;

(q) about 9.0;

(r) about 9.5; and

(s) about 10.0.

29 . (canceled)

30 . The method of claim 1 , wherein said method comprises one or more washing steps prior to dissociating the Fc-containing protein from the sFcRn.

Assignments (2)
CHANGE OF NAME Recorded May 4, 2015
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 035571/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2011
From: MCDONNELL, KEVIN A.
To: BIOGEN IDEC MA INC.
Reel/Frame 027029/0235 →